To evaluate over a period of 6 months the safety and the treatment satisfaction of newly
prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.
This is a non-interventional, prospective, post-authorization, multi-centre cohort study in
patients treated with levocetirizine.
The baseline data will be collected at the visit to the physician when levocetirizine is
prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data
will then be collected during 2 visits occurring within the first 6 months of treatment, as
usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is
after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is
- diagnosis of persistent allergic rhinitis
- first prescription of levocetirizine for this diagnosis for this patient
- age ≥ 2 years
- indications other than those defined in inclusion criteria
- history of allergic or anaphylactic reactions to levocetirizine or other derivatives
and excipients included